Royalty Pharma is excited to announce a $7.5 million donation to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies. Read more here: https://lnkd.in/dchN8eUj
About us
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 17 development-stage product candidates.
- Website
-
http://www.royaltypharma.com
External link for Royalty Pharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Public Company
- Founded
- 1996
Employees at Royalty Pharma
View 119 employees at Royalty Pharma
or
Locations
-
Primary
Get directions
110 East 59th street
33rd floor
New York, New York 10022, US
Updates
-
We are excited to announce the appointment of Greg Raskin as Senior Vice President, Head of Academic Initiatives. Greg will lead Royalty Pharma’s outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center. Read more here: https://lnkd.in/gZWipvX5
-
-
Royalty Pharma is excited to announce an agreement with Neurimmune to acquire a royalty interest in AstraZeneca’s cliramitug for up to $425 million. Cliramitug is a first-in-class TTR-fibril-depleting antibody in Phase 3 development with the potential to reverse the course of ATTR-CM. Read more here: https://lnkd.in/egzEVqQr
-
-
We are excited to announce the appointment of Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. Greg brings strong relationships across the biopharmaceutical ecosystem and over two decades of experience advising healthcare companies in capital raising, strategy, and mergers and acquisitions. He will play a critical role as we continue to scale our business and strengthen our leadership position in the rapidly expanding royalty market. Read more here: https://lnkd.in/eUmxyCeN
-
We are pleased to announce the appointment of Kenneth Sun as Senior Vice President and Head of Asia to expand Royalty Pharma’s global platform, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in the region. Ken has nearly two decades of investment banking experience and brings a deep and strategic understanding of the funding needs created by the incredible innovation occurring across Asia. Royalty Pharma is committed to partnering with biotechnology innovators to build the royalty market in greater Asia, just as Royalty Pharma played a foundational role in establishing the biopharma royalty market in developed markets by working closely with universities, research institutions and biopharma companies over two decades ago. Read more here: https://lnkd.in/euvccJ3c
-
-
Royalty Pharma is pleased to announce a $250 million financing agreement with Zymeworks for royalties on Ziihera, a treatment for HER2-positive gastric and biliary tract cancers. Read more here: https://lnkd.in/eTh9fKqt
-
-
Royalty Pharma is excited to announce an agreement with Denali Therapeutics to acquire a royalty interest in tividenofusp alfa for up to $275 million. Tividenofusp alfa has transformative potential for Hunter syndrome, a rare and life-threatening orphan condition. Read more here: https://lnkd.in/eMJ3iCKn
-